Zhuo Minglei, Chi Yujia, Wang Ziping
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Asia Pac J Clin Oncol. 2020 Oct;16(5):e154-e159. doi: 10.1111/ajco.13365. Epub 2020 Aug 12.
With the development of cancer immunotherapy, the combination strategy is becoming prevalent. Multiple relevant clinical trials are ongoing in this field. However, immune-related adverse events (irAEs) occurred more frequently, showing a different pattern from single-agent therapy. It is necessary for clinicians to learn about the characteristics of AEs from combination immunotherapy, and master the skills to deal with them. In this article, we reviewed presently published data about AEs from combination immunotherapy of cancers. We believe a full-scale view about this new treatment strategy will facilitate oncologists to better understand tumor immune response. With cutting edge knowledge, an experienced team can minimize these AEs and help patients to achieve high-quality long-term survival.
随着癌症免疫疗法的发展，联合治疗策略正变得普遍。该领域正在进行多项相关临床试验。然而，免疫相关不良事件（irAEs）的发生更为频繁，呈现出与单药治疗不同的模式。临床医生有必要了解联合免疫治疗中不良事件的特征，并掌握应对这些事件的技能。在本文中，我们回顾了目前已发表的关于癌症联合免疫治疗不良事件的数据。我们相信，全面了解这一新的治疗策略将有助于肿瘤学家更好地理解肿瘤免疫反应。凭借前沿知识，经验丰富的团队可以将这些不良事件降至最低，并帮助患者实现高质量的长期生存。
